A Look at MacroGenics Inc. (MGNX) Shares in the Recent Past Indicates Growth

MacroGenics Inc. (NASDAQ: MGNX) stock jumped 12.09% on Friday to $5.10 against a previous-day closing price of $4.55. With 1.3 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.33 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.27 whereas the lowest price it dropped to was $4.41. The 52-week range on MGNX shows that it touched its highest point at $28.09 and its lowest point at $2.13 during that stretch. It currently has a 1-year price target of $15.22. Beta for the stock currently stands at 2.06.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MGNX was up-trending over the past week, with a rise of 52.69%, but this was up by 43.66% over a month. Three-month performance surged to 19.72% while six-month performance fell -57.07%. The stock lost -79.11% in the past year, while it has lost -68.22% so far this year. A look at the trailing 12-month EPS for MGNX yields -3.56 with Next year EPS estimates of -2.88. For the next quarter, that number is -0.97. This implies an EPS growth rate of -36.30% for this year and 14.00% for next year.

Float and Shares Shorts:

At present, 61.32 million MGNX shares are outstanding with a float of 58.18 million shares on hand for trading. On Jul 14, 2022, short shares totaled 6.84 million, which was 11.15% higher than short shares on Jun 14, 2022. In addition to Dr. Scott Koenig M.D., Ph.D. as the firm’s Pres, CEO & Director, Mr. James Karrels serves as its Sr. VP, CFO & Corp. Sec..

Institutional Ownership:

Through their ownership of 100.83% of MGNX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 59.54% of MGNX, in contrast to 40.67% held by mutual funds. Shares owned by individuals account for 26.16%. As the largest shareholder in MGNX with 11.94% of the stake, Bellevue Asset Management AG holds 7,325,514 shares worth 7,325,514. A second-largest stockholder of MGNX, RA Capital Management LP, holds 6,103,594 shares, controlling over 9.95% of the firm’s shares. Armistice Capital LLC is the third largest shareholder in MGNX, holding 5,000,000 shares or 8.15% stake. With a 11.86% stake in MGNX, the BB Biotech AG is the largest stakeholder. A total of 7,275,564 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.85% of MGNX stock, is the second-largest Mutual Fund holder. It holds 1,747,951 shares valued at 5.16 million. Wasatch Ultra Growth Fund holds 2.58% of the stake in MGNX, owning 1,585,143 shares worth 4.68 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MGNX since 11 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MGNX analysts setting a high price target of $35.00 and a low target of $4.00, the average target price over the next 12 months is $13.00. Based on these targets, MGNX could surge 586.27% to reach the target high and fall by -21.57% to reach the target low. Reaching the average price target will result in a growth of 154.9% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MGNX will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of -$2.02 being high and -$3.89 being low. For MGNX, this leads to a yearly average estimate of -$2.95. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. MacroGenics Inc. surprised analysts by $0.31 when it reported -$0.67 EPS against a consensus estimate of -$0.98. The surprise factor in the prior quarter was -$0.23. Based on analyst estimates, the high estimate for the next quarter is $0.33 and the low estimate is -$1.12. The average estimate for the next quarter is thus -$0.52.

Summary of Insider Activity:

Insiders traded MGNX stock several times over the past three months with 3 Buys and 1 Sells. In these transactions, 98,265 shares were bought while 1,666 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 1,109,621 while 1,666 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *